Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors	non-small cell lung carcinoma	Not yet recruiting	Phase 2	2026-01-09		NCT07330076

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Tianjin Medical University Cancer Institute and Hospital	287

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.

Clinical trials